Skip to main content

Patient Search

Testimonials Testimonials

Displaying 1 - 3 of 3

Belzutifan / MK-6482 for the Treatment of Advanced Pheochromocytoma / Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), or Von Hippel-Lindau (VHL) Disease-Associated Tumors (MK-6482-015)

Multiple Cancer Types

This is a study to evaluate the efficacy and safety of Belzutifan monotherapy in participants with advanced pheochromocytoma / paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET) or von Hippel-Lindau (VHL) Disease-Associated Tumors. The primary objective of the study is to evaluate the objective response rate (ORR) of belzutifan per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).
Endocrine, Pancreatic
Das, Satya

Near Infrared Autofluorescence Imaging for Identifying Parathyroid Glands during Parathyroidectomy


This trial investigates how well near infrared autofluorescence imaging works in identifying parathyroid glands during surgery to remove one or more parathyroid glands (parathyroidectomy). The parathyroid gland is an important organ in the neck that regulates calcium levels in the body. Thus, it is essential for a surgeon to correctly identify this organ when performing parathyroid surgeries. By assisting the surgeon in correctly identifying a diseased parathyroid gland, the 'PTeye' near infrared autofluorescence imaging device may improve the quality of the operation performed on the patient. This trial may determine if the PTeye truly benefits a patient undergoing surgery for parathyroid disease or not.
Solorzano, Carmen

Neuroblastoma Maintenance Therapy Trial

Multiple Cancer Types

Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg / m2 250 mg / m2 BID (strata 1, 2, 3, and 4) OR 2500 mg / m2 BID (stratum 1B) on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.
Endocrine, Neuroblastoma (Pediatrics), Neuroendocrine, Pediatrics
Pastakia, Devang